Reach Us +1-217-403-9671
Editor - Roderick Adrian Ernest Slavcev | University of Waterloo | 6275
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Roderick Adrian Ernest Slavcev

Roderick Adrian Ernest Slavcev
Roderick Adrian Ernest Slavcev
Department of Pharmaceutical Science
School of Pharmacy
University of Waterloo
University of Waterloo


Roderick Slavcev is an Assistant Professor, Pharmaceutical Sciences at the University of Waterloo, School of Pharmacy and holds the Shopper’s Drug Mart Professor of Business and Entrepreneurship Chair. Holding an MBA specialized in biopharma management and commercialization, Roderick currently directs and delivers the School of Pharmacy. He also created and was instrumental in designing the first Medical Microbiology Laboratory to be offered by a Canadian Pharmacy curriculum.

Research Interest

Mediphage Bioceuticals (MB) and encompasses pharmaceutics, cell biology, genetics, molecular biology, virology and technology transfer within the ultimate aim of bringing new treatments to the global environment, especially less developed countries. MB research projects focus on bacteriophage-based biotechnology and include the use of coliphages and phage-encoded genes and genetic elements to design and construct vectors for the development of novel vaccines, biopharmaceuticals and gene therapy systems, and the identification and application of novel phage genomic anti-bacterial genes to treat and dispose of the clinical culprits of global bacterial infection.



Global Speakers in the subject

Global Experts in the subject